Post-endocytotic Deubiquitination and Degradation of the Metabotropic \(\gamma\)-Aminobutyrinic Acid Receptor by the Ubiquitin-specific Protease 14*

Nicolas Lahaie1, Michaela Kralikova3, Laurent Prézeau2, Jaroslav Blahos2,3, and Michel Bouvier2,4

From the 1Department of Biochemistry and Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec H3T 1J4, Canada, 2Institute of Molecular Genetics, Academy of Science of the Czech Republic, 14220 Prague 4, Czech Republic, and 3Institut de Génomique Fonctionnelle, Université de Montpellier 1 and 2, 34090 Montpellier, France

Mechanisms controlling the metabotropic \(\gamma\)-aminobutyrinic acid receptor (GABA\(_{B}\)) cell surface stability are still poorly understood. In contrast with many other G protein-coupled receptors (GPCR), it is not subject to agonist-promoted internalization, but is constitutively internalized and rapidly downregulated. In search of novel interacting proteins regulating receptor fate, we report that the ubiquitin-specific protease 14 (USP14) interacts with the GABA\(_{B(1b)}\) subunit’s second intracellular loop. Probing the receptor for ubiquitination using bioluminescence resonance energy transfer (BRET), we detected a constitutive and phorbol 12-myristate 13-acetate (PMA)-induced ubiquitination of the receptor at the cell surface. PMA also increased internalization and accelerated receptor degradation. Overexpression of USP14 decreased ubiquitination while treatment with a small molecule inhibitor of the deubiquitinase (IU1) increased receptor ubiquitination. Treatment with the internalization inhibitor Dynasore blunted both USP14 and IU1 effects on the receptor ubiquitination state, suggesting a post-endocytic site of action. Overexpression of USP14 also led to an accelerated degradation of GABA\(_{B}\) in a catalytically independent fashion. We thus propose a model whereby cell surface ubiquitination precedes endocytosis, after which USP14 acts as an ubiquitin-binding protein that targets the ubiquitinated receptor to lysosomal degradation and promotes its deubiquitination.

G protein-coupled receptors (GPCRs)5 are the largest family of cell-surface proteins in the human genome and represent the target of a large proportion of current pharmaceutical agents. Regulation of GPCR activity in response to different stimuli provides cells with important mechanisms to fine tune the response to natural ligands as well as drugs.

For most GPCRs, desensitization results from agonist-promoted phosphorylation by second messenger-activated and GPCR kinases (GRK) (1), leading to \(\beta\)-arrestin-promoted uncoupling from the G protein and subsequent endocytosis. In contrast, the metabotropic \(\gamma\)-aminobutyrinic acid receptor (GABA\(_{B}\)), an obligatory hetero-oligomer composed of two different 7TM proteins, GABA\(_{B(1)}\) and GABA\(_{B(2)}\), which provides the metabotropic response to the inhibitory neurotransmitter GABA (2), does not undergo \(\beta\)-arrestin engagement and receptor endocytosis following agonist stimulation. Two GRK isoforms (GRK4 and GRK5) (3) have been proposed to play a role in GABA\(_{B}\) desensitization. In the case of GRK4, this effect was found to be independent of its kinase activity, as its regulator of G protein signaling (RGS) domain alone is sufficient for desensitization of the receptor (4). Also, in contrast with most GPCR, GABA\(_{B}\) activity is not correlated with the overall phosphorylation state of the receptor. Agonist-promoted protein kinase C (PKC) phosphorylation decreases receptor activity (5) while phosphorylation by adenosine monophosphate activated-kinase (AMPK) on GABA\(_{B(2)}\) serine 783 (6) and by protein kinase A on GABA\(_{B(2)}\) serine 893 (7) have been linked to receptor sensitization and increased effector coupling. Finally, interaction of the receptor with members of the potassium channel tetramerization domain (KCTD) family can also modulate receptor-effector coupling (8), adding yet another level of regulation.

Removal of agonist-desensitized receptor from the cell surface through endocytosis is a common step for GPCR resensitization or degradation (9). However, GABA\(_{B}\) does not undergo agonist-promoted endocytosis (4, 5) but internalizes constitutively at a rapid rate, up to 50% of the receptor being removed from the cell surface in 2 h (10). This phenomenon has been observed in both heterologous expression systems and primary neuron cultures (4, 11). The exact mechanism underlying constitutive internalization is not yet characterized, but it has been suggested that a direct interaction between the GABA\(_{B}\) recep-

---

5 The abbreviations used are: GPCR, G protein-coupled receptors; GABA\(_{B}\), metabotropic \(\gamma\)-aminobutyrinic acid receptor; USP14, ubiquitin-specific protease 14; BRET, bioluminescence resonance energy transfer; ER, endoplasmic reticulum; PMCA, phosphol 12-myristate 13-acetate; GRK, GPCR kinases; PKC, protein kinase C; AMPK, adenosine monophosphate activated-kinase; KCTD, potassium channel tetramerization domain; AP-2, clathrin adaptor protein-2; \(\beta\)-AR, \(\beta\)-adrenergic receptor; Rluc, Renilla Luciferase; YFP, yellow fluorescent protein; Ubi, human ubiquitin; PAR1, protease-activated receptor 1.
USP14 Regulates Post-endocytic Fate of GABA<sub>B</sub>

as well as all the lysine mutants of GABA<sub>B</sub> (pcDNA3-Myc-GABA<sub>B(1b)-KAA-Rluc (K887A/K893A), pcDNA3-Myc-GABA<sub>B(1b)-KKAA-Rluc (K890A/K905A), pcDNA3-Myc-GABA<sub>B(1b)-KKAKA-Rluc (K878A/K893A/K900A/K905A)), and GABA<sub>B(2) (pcDNA3-HA-GABA<sub>B(2)-KAA-Rluc (K767A/K771A), HA-GABA<sub>B(2)-KA4 (K801A/K807A)) and the ER-retention signal mutant of GABA<sub>B(1b) (pcDNA3-Myc-GABA<sub>B(1b)-ASRR-Rluc). CXCX4-Rluc (28) and pcDNA3-V2R-Rluc (29) have been previously described. pcDNA3-PAR1-Rluc was a generous gift from Dr. Terry Hébert (McGill University, Montreal, Canada). Dynasore, chloroquine, PMA, and MG132 were purchased from Sigma-Aldrich while GABA was from Calbiochem, IU1 from Cayman Chemical, coelenterazine h from Nanolight Technology and EZ-Link Sulfo-NHS-LC-Biotin from Thermo Scientific. Poly-d-lysine was from MP Biomedicals while poly-L-lysine was from Gibco. All cell culture reagents were from Wisent or Gibco. All others chemicals were from Sigma. Anti-Myc (9E10) was an ascites fluid prepared in house while anti-GFP was from Clontech (632592). Anti-GABA<sub>B(2) was a generous gift from GlaxoSmithKline (United Kingdom). Anti-Rluc was obtained from Ray Biotechnologies (130–00005). Anti-actin antibody (sc-1616) was from Santa Cruz Biotechnologies. Anti-USP14 antibody (8159), USP14-siRNA and control siRNA were from Cellular Signaling. Anti-mouse IgG (NA931V) and anti-rabbit IgG (NA934V) secondary antibody coupled to horseradish peroxidase were from GE HealthCare Life Sciences. Pep-il2 (VHTVFTKKEKEKWRTLEPYGRKKRR-QRR) and the random sequence peptide pep-RSP (ISH-VCKLFAM-YGRKKRRQRR) were synthesized by GenScript.

Transfection—HEK293T cells were transfected with the indicated plasmids using PEI, as described previously (29). The following day, cells were transferred to a poly-d-lysine-coated 24 well plate (200 000 cells per well). COS7 cells were grown onto poly-L-Lysine-coated coverslips overnight, transiently transfected by calcium phosphate co-precipitation with equal amount of HA-GABA<sub>B(1a)-CFP, cMyc-GABA<sub>B(2)-YFP, or USp14-YFP constructs in pRK5 vector.

Yeast Two-hybrid—Sequence corresponding to the GABA<sub>B(1) second intracellular loop (GB1i2, protein sequence: TKIWWQRRR) and the random sequence peptide pep-RSP (ISH-VCKLFAM-YGRKKRRQRR) were synthesized by GenScript.

Fluorescent Microscopy—24 h post-transfection, DMEM (Gibco) was replaced by PBS and the living COS7 cells were placed under an inverted fluorescent microscope Zeiss Axio-
**USP14 Regulates Post-endocytic Fate of GABAB**

vert 200 m. The fluorescent pictures were processed by MetaMorph software (Molecular Devices).

**Ubiquitination Measurement by BRET**—To measure ubiquitination, a BRET-based assay monitoring the addition of ubiquitin-YFP to GABA<sub>B</sub> subunits linked to Rluc was performed as previously described (26). Briefly, a ubiquitin mutant form of Ubi (mono-Ubi-YFP) in which lysines 48 and 63, the two major sites for polyubiquitination, were mutated to alanine to avoid steric hindrance, quenching or other interference phenomena due to the presence of multiple YFP that could lead to a blunted BRET signal. A ubiquitin-YFP lacking the two terminal glycines required for covalent ubiquitination (UbiAA-YFP) was used as a negative control. Treatments were done directly in 6- or 12-well plates for the indicated time. Medium was then removed, cells washed twice in PBS and resuspended in PBS. 100,000 cells were then transferred to 96-well white plates. BRET measurements were done as described in Ref. 29. In short, cells were treated for 2 min with 5 μM coelenterazine h before reading in a Berthold Mithras LB940 equipped with acceptor (530 ± 20 nm) and donor (480 ± 20 nm) filters. netBRET was calculated as the ratio of the signal detected in the 530 ± 20 nm window (corresponding to the YFP emission) divided by the signal detected in the 480 ± 20 nm window (corresponding to the Rluc emission) when both Rluc and YFP partners were expressed minus the same ratio when only the Rluc partner was expressed. The specific ubiquitination BRET was calculated by subtracting the nonspecific netBRET measured when UbiAA-YFP was expressed as the energy acceptor from the netBRET measured when MonoUbi-YFP was expressed as the energy acceptor.

**Degradation Assay using Biotin Labeling and Streptavidin Precipitation**—Biotin labeling was modified from Ref. 10. HEK293 cells expressing Myc-tagged GABA<sub>B</sub>(1b) and HAtagged GABA<sub>B</sub>(3) were treated with EZ-Link Sulfo-NHS-LC-Biotin (0.5 mg/ml) in buffer A (25 mM HEPES, pH 7.4, 119 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, 30 mM glucose) at 4 °C for 30 min, then washed three times with ice-cold buffer A. Cells were then either kept on ice (control) or treated with the appropriate compound at 37 °C for the indicated chase time. Cells were solubilized in RIPA buffer (50 mM Tric-HCl pH 7.4, 150 mM NaCl, 2.5 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM DTT, 5 μg/ml leupeptin, 5 μg/ml soybean trypsin inhibitor, 10 μg/ml benzamidene) and biotin-labeled receptors purified by pull-down with streptavidin-Sepharose beads and subjected to SDS-PAGE and Western blotting with anti-Myc (9E10) mouse antibody. Quantification of the receptors was done by chemiluminescence using a LAS-3000 from Fujifilm and analyzed using Quantity One software from Bio-Rad.

**Internalization Assay by ELISA**—Two days following transfection, media was removed and cells were washed in ice-cold buffer A. Cells were then incubated with 9E10 anti-Myc antibody (1:1000 in buffer A containing 0.2% BSA) for 1 h on ice, then washed three times in cold buffer A. Cells were then treated or not (vehicle) at 37 °C for 1 h. Following incubation, cells were washed in cold buffer A and incubated with secondary antibody (anti-mouse IgG coupled to horseradish peroxidase) for 45 min. Cells were then washed three times, and the colorimetric ELISA signal was measured after adding SIGMAFAST™

**Immunoprecipitation and Western Blotting**—Immunoprecipitations (IPs) were done as described in (5) using RIPA buffer Anti-Myc antibody was added in a 1:400 dilution. After incubation for 16 h, beads were washed three times with RIPA buffer containing 350 mM NaCl. Remaining complexes were dissolved in Laemmli buffer before being subjected to SDS-PAGE and Western blotting using anti GABA<sub>B</sub>(3) 9E10 anti-Myc, anti-GFP, and anti-Rluc antibodies. To detect USP14 expression after siRNA transfection, cells were lysed and subjected to Western blotting as described above using anti USP14. Actin was used as internal control for normalization.

**Statistical Analysis**—All statistical analysis were done using GraphPad Prism 5.0. Analysis of variance (ANOVA) followed by post hoc Dunnett or Tukey tests were used for multiple comparisons; Dunnett tests being used to compare multiple conditions to a single control, whereas Tukey tests were used to identify the difference within a group. Student’s t tests were performed for pairwise comparison.

**Results**

**Identification of USP14 as a Novel GABA<sub>B</sub> Interactor**—Using the evolutionary conserved second cytoplasmic loop of GABA<sub>B</sub>(1b) as a bait in a yeast two-hybrid screen, we identified a rat cDNA encoding part of the catalytic domain of the Ubiquitin-Specific Protease 14 (USP14) (Fig. 1A). The interaction between USP14 and GABA<sub>B</sub>(1b) in the context of the functional heterodimer was confirmed by co-immunoprecipitation studies in HEK293T cells. As shown in Fig. 1B, GFP-USP14 was detected by Western blot analysis following receptor immunoprecipitation. The appearance of USP14 as a doublet (with two bands separated by ≈3 kDa) may result from a post-translational modification or degradation of a fraction of USP14. Although the precise reason is unknown, similar migration profiles have been previously observed for USP14 (23, 30). Considering that the interacting USP14 cDNA found in the yeast-two-hybrid screen encodes its catalytic domain, we tested whether the interaction was dependent on the deubiquitinase activity of USP14. For this purpose, we took advantage of a mutant form of USP14 (USP14-C79A) which is catalytically inactive (31). Immunoprecipitation revealed that both WT- and USP14-C79A interacted to the same extent with the receptor, suggesting that USP14 deubiquitinase activity is not required for its interaction with GABA<sub>B</sub>(1b).

To assess the specificity of USP14 binding to GABA<sub>B</sub>(1b), we created a membrane-permeable TAT-fused peptide comprising the intracellular 20 amino acids (688 to 707) of the 29-mer sequence from the yeast two-hybrid bait peptide originating from the GABA<sub>B</sub>(1b) second intracellular loop (pep-il2; Fig. 1A). Pre-treatment of cells with pep-il2 completely abolished the co-immunoprecipitation of GFP-USP14 with the functional GABA<sub>B</sub> heterodimer whereas a TAT-fused random sequence peptide was without effect (Fig. 1C), confirming the interaction site to the second intracellular loop of GABA<sub>B</sub>(1b).

**Probing GABA<sub>B</sub> Ubiquitination**—To investigate the potential role of USP14 in the regulation of GABA<sub>B</sub> ubiquitination, we first assessed whether GABA<sub>B</sub> ubiquitination can be mea-
measured in living cells using a BRET-based ubiquitination assay (26). BRET titration curves were obtained using receptor subunits genetically fused to Renilla Luciferase (Rluc) and a genetically engineered ubiquitin (monoUbi) construct linking its N terminus to an enhanced Yellow Fluorescent Protein (YFP) (26). To assess the extent of receptor ubiquitination, an increasing amount of monoUbi-YFP was co-expressed with a constant amount of either GABAB(1b)-Rluc or GABAB(2)-Rluc with the associated untagged partner subunit. A mutated ubiquitin missing the C-terminal glycine residues that cannot be conjugated to its substrate and linked to YFP (UbiAA-YFP) was used as a negative control.

As shown in Fig. 2, increasing Ubi-YFP led to a hyperbolic increase of the BRET signal with either GABAB(1b)-Rluc (Fig. 2A) or GABAB(2)-Rluc (Fig. 2C) when expressed in the presence of their untagged cognate partner subunit (GABA_B(1b)) and GABA_B(2)), respectively. Although random collision between energy donor and acceptors and non-covalent binding of Ubi can contribute to the BRET signal, the saturability of the signal suggests the occupancy of specific ubiquitination sites. The selectivity of the signal is further supported by the observation that the UbiAA-YFP negative control led to much weaker signals that generally increased linearly with increasing concentration of UbiAA-YFP, as could be expected from random collision, and was therefore used as background BRET values (32). The specific ubiquitination signals (inset of Fig. 2, A–C) were therefore calculated by subtracting the background BRET (UbiAA-YFP signal) from the total signal observed. Specific signals were detected, whether the GABAB(1b) or GABAB(2) were tagged with luciferase within the heterodimer. The expression of GABAB(1b)-Rluc alone, which is retained in the ER in the absence of GABAB(2) (Fig. 2E), led to a weaker specific ubiquitination signal (Fig. 2B), suggesting that a significant fraction of the ubiquitination signal originates from plasma membrane receptors. Consistent with this notion, a larger ubiquitination BRET signal is observed when using a mutant form of the GABAB(1) (GABAB(1b)-ASRR) that can reach the plasma membrane in the absence of GABAB(2) as a result of a mutation of GABAB(1b) ER-retention signal (33) (Fig. 2B). Specific ubiquitination was also observed when GABAB(2), which can easily access the cell surface, was expressed alone (Fig. 2D). To study ubiquitination of the functional heterodimer that can reach plasma membrane, the GABA_B(1b)-Rluc/GABA_B(2) pair was used for the rest of the study.
FIGURE 2. BRET titration curves of GABA<sub>B</sub> homo- and heterodimer with MonoUb-YFP or UbiAA-YFP. BRET signal, total fluorescence, and total luminescence were measured in HEK293T cells transfected with constant amount of Myc-GABA<sub>B(1b)</sub>-Rluc and HA-GABA<sub>B(2)</sub> (A), wild-type (WT) Myc-GABA<sub>B(1b)</sub>-Rluc or Myc-GABA<sub>B(1b)-ASRR</sub>-Rluc (B), Myc-GABA<sub>B(1b)</sub> and HA-GABA<sub>B(2)</sub>-Rluc (C) or HA-GABA<sub>B(2)</sub>-Rluc (D) and increasing amount of either MonoUb-YFP or UbiAA-YFP. The data obtained in two independent experiments were pooled and used to generate the curves. The specific ubiquitination BRET curves (inset A–D) were obtained by subtracting the UbiAA-YFP curve from the MonoUb-YFP curve. E, fluorescent microscopy of COS7 cells expressing either HA-GABA<sub>B(1a)</sub>-CFP (left panel) or both HA-GABA<sub>B(1a)</sub>-CFP and cMyc-GABA<sub>B(2)</sub>-YFP (right panel). F, table describing the point mutations in each GABA<sub>B</sub> constructs used. G and H, BRET signal were measured in HEK293T cells expressing the WT and mutants version of Myc-GABA<sub>B(1b)</sub>-Rluc (G) or HA-GABA<sub>B(2)</sub> (H), along with the WT GABA<sub>B</sub> partner subunit and either MonoUb-YFP or UbiAA-YFP. UbiAA-YFP signal was subtracted from MonoUb-YFP signal to generate specific ubiquitination BRET signal. The results are presented as the mean ± S.E. of three independent experiments performed in quadruplicates. (*, p < 0.05; **, p < 0.01.)
To investigate the residues of both GABA<sub>B</sub> subunits potentially involved in receptor ubiquitination, we mutated four lysines that had previously been found to be ubiquitinated in a brain ubiquitome screen (Lys-887 and Lys-905 on GABA<sub>B(1b)</sub>, and Lys-767 and Lys-801 on GABA<sub>B(2)</sub> (34)) to prevent ubiquitination site shifting (Fig. 2F). As shown in Fig. 2F, mutants Myc-GABA<sub>B(1b)-KA1</sub> (K887A/K893A) and Myc-GABA<sub>B(1b)-KA2</sub> (K900A/K905A) showed a significant (<i>p</i> < 0.05) decrease (15 ± 3% and 16 ± 3%, respectively) in receptor ubiquitination, and the combination of the four mutations in Myc-GABA<sub>B(1b)-KKAA</sub> led to a further reduction in BRET signal (27 ± 2%), indicating that the mutated residues represent potential sites of ubiquitination on the GABA<sub>B(1b)</sub> subunit. On the GABA<sub>B(2)</sub> subunit, the previously characterized K767A/K771A mutant (25) (HA-GABA<sub>B(2)-KA3</sub>) showed a 11 ± 3% decrease in BRET signal, while the HA-GABA<sub>B(2)-KA4</sub> (K801A/K807A) mutant showed no significant difference (Fig. 2H). These data indicate that some of the previously identified sites contribute to the basal ubiquitination signal but that additional lysines are also involved.

Stimulation of the receptor with GABA was without effect on the ubiquitination signal (Fig. 3A). Similarly, no effect was observed upon treatment with baclofen or the GABAB inverse agonist CGP54626 (35) (data not shown), indicating that neither agonist-promoted nor constitutive activation of the receptor had a direct effect on its ubiquitination level. Since GABAB activity has long been known to be down-regulated by PKC (36), we assessed the effect of the PKC activator, PMA (phorbol-13-myristate-12-acetate), on receptor ubiquitination. Treatment with PMA led to a transient increase in the ubiquitination signal (163 ± 14%) that peaked at 4 h post-treatment and returned to basal level at 24 h (Fig. 3A). This increase was blocked by pre-treatment with the PKC inhibitor Bisindolylmaleimide I (Fig. 3A, inset), indicating a specific PKC-mediated effect.

**PMA Promotes Faster Degradation and Internalization of GABA<sub>B**

![Image]

**FIGURE 3.** PMA increases ubiquitination and accelerates lysosome-mediated degradation of GABA<sub>B</sub>. A, HEK293T cells expressing Myc-GABA<sub>B(1b)-Rluc</sub>, HA-GABA<sub>B(2)</sub>, and either MonoUbi-YFP or UbIA-YFP were treated or not (vehicle) for the indicated time with either 1 mM GABA, 1 μM PMA and/or 100 nM bisindolylmaleimide I (inset, all 2 h). UbiAA-YFP signal was subtracted from MonoUbi-YFP signal to derive the specific BRET signal. B–D, HEK293T cells expressing Myc-GABA<sub>B(1b)</sub> and HA-GABA<sub>B(2)</sub> were labeled with EZ-Link Sulfo-NHS-LC-Biotin and either kept on ice (control) or switch at 37 °C with vehicle (B) or 100 nM PMA (C) for the indicated time. After cell solubilization, biotin-labeled receptors were purified by pull-down with streptavidin-Sepharose beads and detected by Western blot (WB) with anti-Myc (9E10) mouse antibody. Receptors remaining after the chase period were quantified (D) and t<sub>1/2</sub> was calculated (inset). E–F, as described for B–C, but the temperature switch at 37 °C was done only for 2 h in the presence of vehicle, 200 μg chloroquine or 5 μg/ml MG132. The results shown (B, C, E) are representative of at least three independent experiments or are the mean ± S.E. of at least five (A) or at least three (D, F) independent experiments performed in quadruplicates. (*, <i>p</i> < 0.05; **, <i>p</i> < 0.01; ***, <i>p</i> < 0.001.)
USP14 Regulates Post-endocytic Fate of GABA$_B$

Given that GABA$_B$ has been shown to have a rapid rate of constitutive endocytosis that contributes to degradation (11), the decrease in receptor-half-life detected could result either from an accelerated rate of internalization or a greater targeting of endocytosed receptors to lysosomal degradation. To distinguish between these two possibilities, we assessed the effect of PMA on internalization. For this purpose, we labeled GABA$_B$ heterodimer with Myc-targeted antibody at 4 °C and induced constitutive internalization by switching the temperature to 37 °C, thus monitoring only the disappearance from the plasma membrane. Two hours after temperature switch, 24 ± 4% of the receptor had been internalized under basal condition (Fig. 4A). Treatment with GABA did not increase the extent of internalization, confirming earlier reports that the receptor does not undergo agonist-promoted internalization (4, 39). In contrast, treatment with PMA led to a significant (p < 0.05) increase of endocytosis (33 ± 4%), suggesting that the PMA-accelerated degradation resulted at least in part from an increased internalization.

To probe whether the ubiquitination of the receptor occurs at the cell surface or in the endosomes following internalization, we assessed the effect of a general blocker of dynamin-dependent endocytosis, Dynasore, on both receptor internalization and ubiquitination. Dynasore significantly (p < 0.01) blunted both constitutive (54 ± 7% inhibition) and PMA-induced (63 ± 9% inhibition) internalization (Fig. 4A). The Dynasore-mediated block in endocytosis was accompanied by a statistically significant (p < 0.001) 29 ± 3% increase in the basal ubiquitination (Fig. 4B), suggesting that at least part of the modification occurs before internalization of the receptor. Co-treatment with both PMA and Dynasore led to an additive increase in BRET signal (Fig. 4B), indicating that a substantial part of the PMA-promoted increase in ubiquitination also occurs at the plasma membrane.

**USP14 Regulates GABA$_B$ Ubiquitination and Degradation**—To assess the potential role of USP14 in GABA$_B$ regulation, we first determined the effect of the deubiquitinase overexpression on the ubiquitination state of the receptor. Co-expression of USP14 with the GABA$_B$ receptor led to a 25 ± 4% decrease in receptor ubiquitination whereas the catalytically inactive mutant form of the deubiquitinase, USP14-C79A, did not affect the basal level of ubiquitination (Fig. 5A), indicating that USP14 catalyzed GABA$_B$ deubiquitination. Furthermore, both treatment with IU1, a recently discovered inhibitor of USP14 (31), and Pep-pi2, the cell-permeable USP14/GABA$_B$(1b) interaction blocking peptide, led to a significant (p < 0.01) increase in
GABA<sub>B</sub> ubiquitination (Fig. 5, B and C). The observation that IU1 (Fig. 5B) increased GABA<sub>B</sub> ubiquitination in cells overexpressing or not USP14 and that Pep-il2 (Fig. 5C) also inhibited the ubiquitination in cells endogenously expressing USP14 suggests that this enzyme is responsible for the endogenous constitutive deubiquitination of the receptor through a direct protein-protein interaction. To assess whether USP14 acts as a general deubiquitination enzyme of GPCRs, we tested the effect of USP14 overexpression on 3 additional receptors. As previously reported (23), USP14 reduced CXCR4 ubiquitination (Fig. 5D). Similarly, the ubiquitination level of the type-2 vasopressin receptor was also decreased by the enzyme whereas it did not alter PAR-1 ubiquitination, suggesting some level of selectivity in its GPCR substrates.

Given the proposed roles of ubiquitination on the internalization and degradation of membrane proteins, we assessed the effect of USP14 on these processes for the GABA<sub>B</sub>. Co-expression of USP14 with GABA<sub>B</sub> lead to a significant acceleration of the degradation rate of the receptor, reducing the half-life of the receptor from 3 h to less than 1 h (Fig. 6, A, B, G). Surprisingly, the catalytically inactive USP14-C79A, which could not promote deubiquitination of GABA<sub>B</sub> (Fig. 5A), accelerated receptor degradation to the same extent as the WT form of the enzyme (Fig. 6, C and G), suggesting that the USP14-promoted degradation is independent of its deubiquitinate activity. Consistent with this notion, treatment of cells with the USP14 inhibitor IU1 did not significantly affect degradation (Fig. 6, D and G), also suggesting that the deubiquitinate activity of USP14 does not contribute to GABA<sub>B</sub> degradation. In contrast, treatment with the Pep-il2 blocking peptide significantly slowed down receptor disappearance whereas treatment with the Pep-RSP had no significant difference (Fig. 6, E–G), indicating the importance of the USP14/GABA<sub>B</sub> protein-protein interaction in the USP14-mediated receptor degradation. Contrary to the PMA treatment, which increased both the degradation and the endocytosis of the receptor, neither USP14 overexpression nor IU1 treatment affected the extent of internalization (Fig. 6H), indicating that USP14-promoted GABA<sub>B</sub> degradation is independent of the receptor internalization rate, suggesting a post-endocytic mechanism.

To confirm the importance of endogenous USP14 toward GABA<sub>B</sub> deubiquitination and degradation, we knocked-down the expression of the deubiquitinase using siRNA (Fig. 7A). This knock-down led to a significant increase in GABA<sub>B</sub> ubiquitination (p < 0.01) and a reduced rate of degradation.
USP14 Regulates Post-endocytic Fate of GABA<sub>B</sub>

**FIGURE 6.** USP14 accelerates the degradation rate of GABA<sub>B</sub> independently of its catalytic activity. A–G, HEK293T cells expressing Myc-GABA<sub>B</sub>(1b)HA-GABA<sub>B</sub>(2) and either pcDNA3 (A, D–F), USP14 (B) or USP14-C79A (C) were labeled with EZ-Link Sulfo-NHS-LC-Biotin and treated or not (vehicle, A–C) with either 100 μM IU1 (D), 10 μM Pep-RSP (E), or 10 μM Pep-il2 (F) for the indicated time, as described in Fig. 3. The receptors remaining after the chase period were quantified and half-life calculated (G). H, HEK293T cells expressing Myc-GABA<sub>B</sub>(1b)-Rluc, HA-GABA<sub>B</sub>(2) and either pcDNA3 or USP14 were labeled with anti-Myc 9E10 antibody for one hour on ice. Internalization was induced by temperature switch to 37 °C for 2 h in the absence (vehicle) or presence of 100 μM IU1. Control cells were kept on ice. Receptor amount still at the cell surface were measured by ELISA. The results shown are representative of three independent experiments (A–F) or are the mean ± S.E. of at least three independent experiments performed in triplicates (G, H). (*, p < 0.05.)

In increased receptor half-life) (p < 0.05) compared with a control siRNA (Fig. 7, B–E).

**USP14 Acts as a Post-endocytosis Regulator of GABA<sub>B</sub>**—To determine whether USP14 acts pre- or post-endocytosis, its deubiquitination activity was tested in the presence and absence of the internalization inhibitor Dynasore. As shown in Fig. 8A, treatment with Dynasore led to a time-dependent decrease of the deubiquitination promoted by USP14 overexpression, indicating a post-endocytosis action of USP14.

Indeed, overexpressing USP14 resulted, as expected, in an overall reduction of the ubiquitination state of the receptor. However, inhibiting endocytosis with Dynasore significantly blunted the effect of USP14, the reduction in GABA<sub>B</sub> ubiquitination promoted by USP14 overexpression going from 21% to 9% following a 16h Dynasore treatment (Fig. 8A, inset). Also consistent with the post-endocytic action of USP14, the increased GABA<sub>B</sub> ubiquitination observed following inhibition of USP14 by IU1 was blunted from 23% to 8% following Dyna-
sore treatment (Fig. 8B, inset). Together, these data clearly suggest that most of the deubiquitination action of USP14 occurs following endocytosis since a pre-endocytic action of USP14 would have been potentiated, not blunted by inhibiting endocytosis. This is also consistent with a primarily cytoplasmic localization of USP14 (Fig. 8C). Of notice, the deubiquitinating activity of USP14 was not affected by inhibition of lysosomal degradation with chloroquine (Fig. 8D). The observation that chloroquine treatment increased ubiquitination signal in the presence or absence of overexpressed USP14, is consistent with the lysosomal degradation of the ubiquitinated receptor.

Discussion

In the present study, we showed that GABAB is constitutively ubiquitinated in living cells and that this post-translational modification occurs, at least in part, once the receptor has reached the cell surface. Increased ubiquitination promoted by PKC activation is accompanied by an increase in GABAB internalization and accelerated degradation. Deubiquitination of the receptor is catalyzed post-endocytically by the deubiquitinase USP14 that contributes to the targeting of the receptor for lysosomal degradation. In addition, to further our understanding of the constitutive ubiquitination and cell surface regulation of GABAB, our study unravels a new PKC-mediated regulation of this post-translational modification and identifies USP14 as an important regulator of both receptor ubiquitination and degradation.

USP14 is a member of the ubiquitin-specific proteases (USPs)/ubiquitin-specific-processing proteases (UBPs) family of proteases, falling into subfamily of Peptidases C19.
family is, with around 60 members, one of the largest families of peptidases in the human genome (40). These intracellular peptidases remove ubiquitin molecules from poly-ubiquitinated peptides by cleavage of isopeptide bonds, through the hydrolysis of carboxyl group bonds of the extreme C-terminal glycine residue of ubiquitin. The level of sequence conservation varies considerably among the members of the family. USP14 displays diverse sequence identity with the other members of the family, depending on varying regions outside the catalytic core. In the catalytic domain, the conservation of USP14 reaches between 18 and 26% with the other members. Despite the relatively low sequence identity, residues surrounding the catalytic cysteine and histidine are conserved and the overall fold of the catalytic domain seems preserved among these enzymes (41).

As mentioned, in addition to the catalytic domain, USPs also harbor diverse accessory domains that are believed to confer selectivity for the regulation of their catalytic activity, substrate recognition, recruitment of regulatory factors and subcellular localization. USP14 contains a single ubiquitin-like domain on the N terminus that has been proposed to be its main site of interaction with the proteasome (40).

Given that mutation that abolished the catalytic activity of USP14 did not prevent the interaction between the deubiquitinating enzyme and the receptor nor its ability to promote the lysosomal-dependent degradation of GABA<sub>B</sub>, the role played by each of these domains on the binding and degradation of GABA<sub>B</sub> remains to be determined. Whether USP family members act similarly on GABA<sub>B</sub> or other GPCRs also remains a largely unanswered question, although USP8 has been shown to promote CXCR4 trafficking and degradation (24).

A role for PKC in the regulation of GABA<sub>B</sub> had been previously suggested, as PKC has been shown to phosphorylate GABA<sub>B</sub> (5) and down-regulate synaptic activity of the receptor (36). Although the role of PKC-mediated phosphorylation in GABA<sub>B</sub> ubiquitination remains to be investigated, phosphorylation of other substrates, such as the gap junction protein connexin-43 (42) and the organic anion transporter-1 (43) by PKC has been shown to promote their ubiquitination, resulting in their degradation and internalization, respectively. In the case of GABA<sub>B</sub>, we found that inhibition of endocytosis led to an increased level of both constitutive and PMA-induced ubiquitination, indicating that the PKC-promoted modification occurred at least in part at the plasma membrane and preceded endocytosis. Combined with our observation that PMA treatment led to an elevation of both ubiquitination and endocytosis, these results are consistent with the findings for other membrane proteins that PMA increases ubiquitination and promotes endocytosis (44). In contrast, receptor ubiquitination at the plasma membrane was found to inhibit the constitutive internalization of another GPCR, PAR1, whereas agonist-pro-

FIGURE 8. USP14 deubiquitination is decreased by internalization inhibitor Dynasore. HEK293T cells were transfected with Myc-GABA<sub>B</sub><sup>1b</sup>, HAGABA<sub>B</sub><sup>2b</sup>, MonoUbi-YFP or UbiIA-YFP, and either pcDNA3 or USP14. A, cells were treated or not (vehicle) for two or sixteen hours with 50 μM Dynasore and specific BRET ubiquitination signal calculated. Inset shows the percentage of inhibition of USP14 and calculated as in Fig. 5C. B, cells were treated or not (vehicle) for 2 h with 50 μM Dynasore, with or without IU1. Inset shows the percentage of IU1 induced BRET: IU1 treated minus vehicle dividing by vehicle condition. C, fluorescent microscopy illustrating the cytoplasmic distribution of USP14-YFP in COS7 cells co-expressing HA-GABA<sub>B</sub><sup>1b</sup>-CFP, cMyc-GABA<sub>B</sub><sup>2b</sup>-YFP. D, cells transfected as in A were treated or not (vehicle) for 2 h with 200 μM chloroquine and specific BRET ubiquitination signal calculated. Inset shows the percentage of inhibition of USP14 and calculated as in Fig. 5C. The results are presented as the mean ± S.E. of at least three independent experiments performed in triplicates. (*, p < 0.05; ***, p < 0.001.)
moted deubiquitination favored its endocytosis (18). It should be emphasized, however, that PAR1 may represent a special case since this receptor is activated by proteolytic cleavage of its N terminus, resulting in a continuous activation that requires degradation for its inactivation. Further studies will be needed to determine whether ubiquitination directly favors internalization of GABA<sub>B</sub> through the recruitment of endocytosis machinery elements.

We have identified six potential residues (Lys-887, Lys-893, Lys-900, and Lys-905 on GABA<sub>B(1)</sub>, Lys-767 and Lys-771 on GABA<sub>B(2)</sub>) involved in ubiquitination of GABA<sub>B</sub>. Three of those residues (Lys-887 and Lys-905 on GABA<sub>B(1)</sub> and Lys-767 on GABA<sub>B(2)</sub>) had been found to be ubiquitinated in the human brain (34) and both Lys-767 and Lys-771 have been linked to proteasomal degradation of GABA<sub>B</sub> through a mechanism involving Rpt6 (25, 45). Lys-893 and Lys-900, however, represent novel ubiquitination sites revealed by our study. Whether these sites are responsible for the cell surface ubiquitination or the ubiquitination associated with the ERAD system remains to be investigated. Proteasomal degradation has been previously shown to affect the expression of GABA<sub>B</sub> but was linked to the ER and forward trafficking of the receptor (25). Our findings identify yet another and distinct cell-membrane and post-endocytic role for ubiquitination and USP14.

The observation that stimulation of GABA<sub>B</sub> by its agonists GABA and baclofen did not affect the extent of receptor ubiquitination contrasts with what was observed for several GPCRs, such as the β<sub>2</sub>AR (16, 19) and CXCR4 (38). In those cases, agonist-promoted β-arrestin recruitment brings E3 ubiquitin ligases to the receptors, promoting ubiquitination. In contrast, GABA<sub>B</sub> stimulation has not been found to promote β-arrestin recruitment and internalization (4, 39), nor to promote receptor down-regulation (11), consistent with the lack of agonist-stimulated ubiquitination observed. The process leading to the constitutive ubiquitination of GABA<sub>B</sub> and the identity of the E3 ligase involved remains to be investigated. However, our data clearly identify USP14 as a deubiquitinase that regulates the ubiquitination state of GABA<sub>B</sub>. This action of USP14 was blocked by an inactivating mutation of its catalytic domain, indicating that this diminution is due to deubiquitination of the receptor and not to a decrease in <i>de novo</i> receptor ubiquitination. The USP14 deubiquitination was significantly blunted when the endocytic process was inhibited by Dynasore, indicating that the deubiquitination occurred following the internalization of the receptor. While Dynasore may have off-target actions, its effect on deubiquitination is consistent with the observation that USP14 overexpression led to an accelerated rate of GABA<sub>B</sub> lysosomal degradation, while siRNA-promoted knock-down of USP14 led to a decreased rate of receptor removal. Such a role for USP14 in the post-endocytic processing of GPCRs has been observed for the CXCR4. Indeed, knock-down of USP14 expression was found to block receptor degradation following stimulation with its agonist CXCL12 (23).

In contrast to its proposed role in the deubiquitination-promoted degradation of CXCR4 (23), the USP14-accelerated rate of degradation of GABA<sub>B</sub> observed in our study was found to be independent of its catalytic activity. The inactive enzyme showed a similar ability to decrease the receptor’s half-life as its wild type counterpart. This was dependent on its interaction with GABA<sub>B</sub>, as the cell-permeable Pep-il2 peptide promoted an increase receptor half-life, most likely by preventing interaction with endogenous USP14. These results suggest that USP14 action on the GABA<sub>B</sub> receptor stability results from direct interaction with the receptor and is not a by-product of the deubiquitination. Such a non-catalytic action of USP14 has been proposed for its role on the activation of the 205 proteasome. Indeed, direct interaction between USP14 and the ubiquitin chain was found to promote the opening of the proteasome, leading to the degradation of the deubiquitinase cargo (46, 47). The data obtained herein for the GABA<sub>B</sub> are however at variance with this canonical role of USP14 as a proteasomal-associated deubiquitinase (31, 46, 47), since we found the USP14-promoted GABA<sub>B</sub> degradation to be lysosomal- and not proteasomal-dependent. It is presently unknown whether, as is the case for its proteasomal role (47), USP14 could act both as a substrate targeting receptor and degradation activator at the lysosome. It is noteworthy that USP14 has also been suggested to be involved in ERAD-associated proteasomal degradation of GABA<sub>B</sub> as IU1 treatment was found to decrease receptor trafficking to the cell surface (25), indicating that USP14-mediated deubiquitination can have distinct actions on GABA<sub>B</sub> steady-state levels. Again, this is distinct from the catalytic-independent GABA<sub>B</sub> degradation-promoting activity of USP14 described in the present study.

Taken together, our results suggest a novel mechanism controlling GABA<sub>B</sub> cell surface expression that involves receptor ubiquitination and the binding of USP14 to promote receptor degradation. The proposed model (Fig. 9) shows cell surface ubiquitination of the GABA<sub>B</sub> receptor occurring constitutively or promoted by PMA. Upon endocytosis, USP14 acts as a catalytically-independent ubiquitin-binding protein to promote endosomal sorting of highly ubiquitinated GABA<sub>B</sub> toward lysosomal degradation. The USP14-promoted deubiquitination of GABA<sub>B</sub> is not needed for its sorting and degradation-promoting activity, as illustrated by the ability of the catalytically-inactive USP14-C79A to lead to lysosomal degradation. The deubiquitinase activity in this model may however be important for ubiquitin recycling, as previously suggested for USP14 (46). Our data suggest that increased ubiquitination of GABA<sub>B</sub> can coexist with faster degradation (ie: when USP14-C79A is overexpressed). There is therefore no need to invoke the action of another deubiquitinase before lysosomal degradation but we cannot exclude the contribution of such another enzyme. In such a model, non-ubiquitinated receptor would not bind to USP14 and would be targeted toward the recycling pathway, allowing reinsertion of the receptor in the plasma membrane and leading to the resensitization of the cells to GABA stimulation. Interestingly, glutamate has been shown to promote internalization (14) and down-regulation of GABA<sub>B</sub> (15) that involves a balance between receptor recycling and degradation (49) in which ubiquitination plays an important role, mirroring multiple elements from our proposed model. Possible activation of PKC by glutamate or others physiological stimuli could provide a general mechanism of regulation of GABA<sub>B</sub> activity, as we have observed that stimulation of endog-
enous muscarinic receptors with carbachol also leads to increased GABA$_B$ ubiquitination (data not shown). It is also tempting to speculate that the constitutively active isoform of PKC, PKM$\zeta$, involved in long-term potentiation maintenance could act in part by down-regulating GABA$_B$ activity (50). Further studies are needed to examine the possible links between various physiological stimuli and the USP14-promoted degradation of GABA$_B$.

The proposed role of USP14 in receptor regulation may have important physiological consequences. Indeed, a transgenic mouse model with an invalidated USP14 gene (USP14 knockout), also known as the ataxia mice, shows profound defects in synaptic transmission (51). These defects have been shown to result in part from an increased GABA$_A$ cell surface expression and activity that is due to altered endosomal sorting and decreased receptor degradation (52), suggesting a similar role of USP14 on GABA$_A$ and GABA$_B$. Also, the ataxia mice show a reduction in the size of the releasable vesicle pool that results in altered neurotransmitter release (53). The GABA$_B$ receptor being directly involved in regulating vesicle priming at the release site (54), it is tempting to speculate that USP14 knockdown promotes increased level of synaptic GABA$_B$ receptor through reduced degradation, leading to an amplified GABA$_B$ activity and reduced releasable vesicle priming. Consistent with this hypothesis, the decreased size of the releasable vesicle pool was rescued by expression of the catalytically inactive USP14 mutant (48), mirroring our finding of a catalytic-independent role of USP14.

In conclusion, our study reveals a new PKC-mediated regulatory mechanism controlling GABA$_B$ ubiquitination, endocytosis and degradation and identifies USP14 as a deubiquitinating enzyme that regulates the post-endocytic ubiquitination state and degradation of the GABA$_B$ with potential implications for synaptic transmission.

**Author Contributions**—N. L. conceived, performed, and analyzed all the experiments described in Figs. 1 to 8 (except the yeast-two hybrid experiments) and wrote the paper. M. K. conceived, performed, and analyzed the experiments related to the yeast two hybrid screen, identifying USP14 as an interactor of GABA$_B$, and the fluorescence microscopy as well as generated constructs that were used in the study. L. P. coordinated the study and wrote the paper. J. B. coordinated the study and wrote the paper. M. B. conceived and coordinated the study and wrote the paper. All authors analyzed the results and approved the final version of the manuscript.

**Acknowledgments**—We thank Dr. Pavel Osten for yeast two hybrid methodology and Dr. Monique Lagace for her expert assistance throughout these studies and her critical reading of the manuscript.

**References**

1. Luttrell, L. M., and Lefkowitz, R. J. (2002) The role of (beta)-arrestins in the termination and transduction of G-protein-coupled receptor signals. *J. Cell Sci.* **115**, 455–465

2. White, J. H., Wise, a, Main, M. J., Green, A., Fraser, N. J., Disney, G. H., Barnes, A. A., Emson, P., Foord, S. M., and Marshall, F. H. (1998) Heterodimerization is required for the formation of a functional GABA(B) receptor. *Nature* **396**, 679–682

3. Kanaide, M., and Uezono, Y. (2007) Desensitization of GABA$\beta$ receptor signaling by formation of protein complexes of GABAB2 subunit with GRK4 or GRK5. *J. Cell Physiol.* **210**, 237–245

4. Perroy, J., Adam, L., Qanbar, R., Chénier, S., and Bouvier, M. (2003)
Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. *EMBO J.* **22**, 3816–3824

5. Pontier, S. M., Lahaye, N., Ginham, R., St-Gelais, F., Bonin, H., Bell, D. J., Flynn, H., Trueude, L.-E., McClainney, J., White, J. H., and Bouvier, M. (2006) Coordinated action of NSF and PKC regulates GABAB receptor signaling efficacy. *EMBO J.* **25**, 2698–2709

6. Kuramata, N., Wilkins, M. E., Fairfax, B. P., Reville-Sanchez, R., Terunuma, M., Tamaki, F., Leidl, M., Warren, N., Coute, A., Calver, A., Horvath, Z., Freeman, K., Carling, D., Huang, L., Gonzalez, C., Cooper, E., Smart, T. G., Pancoska, M. N., and Moss, S. J. (2007) Phospho-dependent functional modulation of GABAB receptors by the metabolic sensor AMP-dependent protein kinase. *Neuron* **53**, 233–247

7. Coute, A., Thomas, P., Calver, A. R., Hirst, W. D., Pancoska, M. N., Walsh, F. S., Smart, T. G., and Moss, S. J. (2002) Cyclic AMP-dependent protein kinase phosphorylation facilitates GABAB receptor-effector coupling. *Nat. Neurosci.* **5**, 415–424

8. Schwenk, J., Metz, M., Zilles, G., Turecek, R., Fritzsche, T., Bildl, W., Tarusawa, E., Kulik, A., Unger, A., Ivanovka, K., Sedik, R., Tiao, J. Y., Rajalu, M., Trojanova, J., Rohde, V., Gassmann, M., Schulte, U., Fakler, B., and Bettler, B. (2010) Native GABAB(B) receptors are heteromultimers with a family of auxiliary subunits. *Nature* **465**, 231–235

9. Hanyaloglu, A. C., and von Zastrow, M. (2008) Regulation of GPCRs by endocytic membrane trafficking and its potential implications. *Annu. Rev. Pharmacol. Toxicol.* **48**, 537–568

10. Gramp, T., Sauter, K., Markovic, B., and Benke, D. (2008) γ-Aminobutyric acid type B receptors are constitutively internalized via the clathrin-dependent pathway and targeted to lysosomes for degradation. *J. Biol. Chem.* **282**, 24157–24165

11. Gramp, T., Notz, V., Broll, I., Fischer, N., and Benke, D. (2008) Constitutive, agonist-accelerated, recycling and lysosomal degradation of GABA(B) receptors in cortical neurons. *Mol. Cell Neurosci.* **39**, 628–637

12. Vargas, K. J., Terunuma, M., Tello, J. A., Pancoska, M. N., Moss, S. J., and Coute, A. (2008) The availability of surface GABA(B) receptors is independent of γ-aminobutyric acid but controlled by glutamate in central neurons. *J. Biol. Chem.* **283**, 24641–24648

13. Terunuma, M., Vargas, K. J., Wilkins, M. E., Ramirez, O. A., Jareguiberry-Bravo, M., Pancoska, M. N., Smart, T. G., Moss, S. J., and Coute, A. (2010) Prolonged activation of NMDA receptors promotes dephosphorylation and alters postendocytic sorting of GABAB receptors. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 13918–13923

14. Guert, N., Aziz, S. A., Holbro, N., Turecek, R., Rose, T., Sedik, R., Gassmann, M., Moes, S., Jenoe, P., Oertner, T. G., Casanova, E., and Betler, B. (2010) NMDA receptor-dependent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. *J. Biol. Chem.* **285**, 34666–34673

15. Breton, B., Lagacé, M., and Bouvier, M. (2010) Combining resonance energy transfer methods reveals a complex between the α2A-adrenergic receptor, Gα11-β1γ2, and GRK2. *FASEB J.* **24**, 4733–4743

16. Nagai, A., Kadovaki, H., Maruyama, T., Takeda, K., Nishihot, H., and Ichijo, H. (2009) USP14 inhibits ER-associated degradation via interaction with IRE1α. *Biochem. Biophys. Res. Commun.* **379**, 995–1000

17. Lee, B.-H., Lee, M. J., Park, S., Oh, D.-C., Elssasser, S., Chen, P.-C., Gartner, C., Dimova, N., Hanna, J., Gygi, S. P., Wilson, S. M., King, R. W., and Finley, D. (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. *Nature* **467**, 179–184

18. Mercier, J.-F., Salahpour, A., Angers, S., Breit, A., and Bouvier, M. (2002) Quantitative assessment of β1- and β2-adrenergic receptor homo- and heterodimers by bioluminescence resonance energy transfer. *J. Biol. Chem.* **277**, 44925–44931

19. Margeta-Mitrovic, M., Jan, Y. N., and Jan, L. Y. (2001) Function of GB1 and GB2 subunits in G protein coupling of GABAB receptors. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 14649–14654

20. Na, C. H., Jones, D. R., Yang, Y., Wang, X., Xu, Y., and Peng, J. (2012) Synaptic protein ubiquitination in rat brain revealed by antibody-based ubiquitome analysis. *J. Proteome Res.* **11**, 4722–4732

21. Mukherjee, R. S., Mchride, E. W., Beinborn, M., Dunlap, K., and Kopin, A. S. (2006) Point mutations in either subunit of the GABAB receptor confer constitutive activity to the heterodimer. *Mol. Pharmacol.* **70**, 1406–1413

22. Dutar, P., and Nicoll, R. A. (1988) Pre- and postsynaptic GABAB receptors in the hippocampus have different pharmacological properties. *Neuron* **1**, 585–591

23. Jacob, C., Cottrell, G. S., Gehringer, D., Schmidlin, F., Grady, E. F., and Bunnett, N. W. (2005) c-Cbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2. *J. Biol. Chem.* **280**, 16076–16087

24. Marchese, A., Benovic, J. L. (2001) Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. *J. Biol. Chem.* **276**, 45509–45512

25. Fairfax, B. P., Pitcher, J. A., Scott, M. G. H., Calver, A. R., Pancoska, M. N., Moss, S. J., and Coute, A. (2004) Phosphorylation and chronic agonist treatment atypically modulate GABAB receptor cell surface stability. *J. Biol. Chem.* **279**, 12565–12573

26. Cugelig, M. J., Barsukov, I., Coulson, J. M., Liu, H., Rigden, D. J., and Urbé, S. (2013) Deubiquitylation from genes to organism. *Physiol. Rev.* **93**, 1289–1315
41. Hu, M., Li, P., Song, L., Jeffrey, P. D., Chenova, T. A., Wilkinson, K. D., Cohen, R. E., and Shi, Y. (2005) Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 24, 3747–3756
42. Leithe, E., and Rivedal, E. (2004) Ubiquitination and down-regulation of gap junction protein connexin-43 in response to 12-O-tetradecanoylphorbol 13-acetate treatment. J. Biol. Chem. 279, 50089–50096
43. Li, S., Zhang, Q., and You, G. (2013) Three ubiquitination sites of organic anion transporter-1 synergistically mediate protein kinase C-dependent endocytosis of the transporter. Mol. Pharmacol. 84, 139–146
44. Haglund, K., and Dikic, I. (2012) The role of ubiquitylation in receptor endocytosis and endosomal sorting. J. Cell Sci. 125, 265–275
45. Zemoura, K., and Benke, D. (2014) Proteasomal degradation of γ-aminobutyric acidB receptors is mediated by the interaction of the GABAB2 C terminus with the proteasomal ATPase Rtp6 and regulated by neuronal activity. J. Biol. Chem. 289, 7738–7746
46. Peth, A., Besche, H. C., and Goldberg, A. L. (2009) Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol. Cell 36, 794–804
47. Peth, A., Kukushkin, N., Bossé, M., and Goldberg, A. L. (2013) Ubiquitinated proteins activate the proteasomal ATPases by binding to Usp14 or Uch37 homologs. J. Biol. Chem. 288, 7781–7790
48. Walters, B. J., Hallengren, J. J., Theile, C. S., Ploegh, H. L., Wilson, S. M., and Dobrunz, L. E. (2014) A catalytic independent function of the deubiquitinating enzyme USP14 regulates hippocampal synaptic short-term plasticity and vesicle number. J. Physiol. 592, 571–586
49. Kuramoto, N., Ito, M., Saito, Y., Niihara, H., Tanaka, N., Yamada, K.-I., Yamamura, Y., Iwasaki, K., Onishi, Y., and Ogita, K. (2013) Deposphorylation of endogenous GABA(B) receptor R2 subunit and AMPK α subunits which were measured by in vitro method using transfer membrane. Neurochem. Int. 62, 137–144
50. Yao, Y., Kelly, M. T., Sajikumar, S., Serrano, P., Tian, D., Bergold, P. J., Frey, J. U., and Sacktor, T. C. (2008) PKMζ maintains late-LTP by NSF/GluR2-dependent trafficking of postsynaptic AMPAR receptors. J. Neurosci. 28, 7820–7827
51. Wilson, S. M., Bhattacharyya, B., Rachel, R. A., Coppola, V., Tessarollo, L., Householder, D. B., Fletcher, C. F., Miller, R. J., Copeland, N. G., and Jenkins, N. A. (2002) Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat. Genet. 32, 420–425
52. Lappe-Siefke, C., Loebrich, S., Hevers, W., Waidmann, O. B., Schweizer, M., Fehr, S., Fritschy, J.-M., Dikic, I., Eilers, J., Wilson, S. M., and Kneussel, M. (2009) The ataxia (axJ) mutation causes abnormal GABAA receptor turnover in mice. PLoS Genet. 5, e1000631
53. Bhattacharyya, B. I., Wilson, S. M., Jung, H., and Miller, R. J. (2012) Altered neurotransmitter release machinery in mice deficient for the deubiquitinating enzyme Usp14. Am. J. Physiol. Cell Physiol. 302, C698–708
54. Sakaba, T., and Neher, E. (2003) Direct modulation of synaptic vesicle priming by GABA(B) receptor activation at a glutamatergic synapse. Nature 424, 775–778